ArticleNanoscale advances2025
Correction: Development and
Muhammad Sarfraz, Gautam Behl, Sweta Rani, Niall O'Reilly, Peter McLoughlin, Orla O'Donovan, Alison L Reynolds, John Lynch, Laurence Fitzhenry
Abstract readPublished Erratum
In one paragraphArticle in Nanoscale advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Muhammad SarfrazOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Gautam BehlOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Sweta RaniOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Niall O'ReillyOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Peter McLoughlinOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Orla O'DonovanOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Alison L ReynoldsUCD School of Veterinary Medicine Dublin Ireland.
John LynchOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Laurence FitzhenryOcular Therapeutics Research Group (OTRG), Pharmaceutical & Molecular Biotechnology Research Centre (PMBRC), South East Technological University Waterford X91 KOEK Waterford Ireland muhammad.sarfraz@setu.ie.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
[This corrects the article DOI: 10.1039/D4NA01086H.].
Identifiers
PMID40322461
PMCPMC12046346
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390